Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per confrontare la terapia standard per trattare il linfoma di Hodgkin con l'uso di due farmaci, Brentuximab Vedotin e Nivolumab

4 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio randomizzato di fase 3 con risposta provvisoria adattata che confronta la terapia standard con la terapia immuno-oncologica per bambini e adulti con linfoma di Hodgkin classico di stadio I e II di nuova diagnosi

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.

SECONDARY OBJECTIVES:

I. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a RER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To evaluate the overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a SER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

III. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients.

IV. To evaluate in patients with newly diagnosed early stage cHL the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in the overall cohort, in the favorable risk cohort, and in the unfavorable risk cohort.

V. To evaluate the event-free survival (EFS) at 12 years of patients undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab).

VI. To compare the physician-reported treatment-related adverse event (AE) rates between a standard chemotherapy approach and an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL.

VII. To compare patient-reported adverse events using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), stratified by age groups, therapeutic arms, and receipt of radiation therapy (RT) over time.

VIII. To evaluate changes in patient-reported fatigue, cognitive functioning, and health-related quality of life (HRQoL), e.g., emotional, physical, and role functioning, by treatment arm, using validated adult and pediatric measurement systems.

IX. To evaluate self-reported late morbidities (e.g., cardiovascular, pulmonary and endocrine) over time for children, adolescents and adults undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab) with and without RT using measures from the St. Jude Lifetime Cohort Study (SJLIFE).

X. To evaluate fludeoxyglucose F-18 (FDG)-position emission tomography (PET) measurements of metabolic tumor burden (MTV and total lesion glycolysis [TLG]) at PET at baseline (PET1) as a predictive marker of PFS.

XI. To evaluate the associations between race/ethnicity and key outcomes including early response to therapy, PFS and OS.

EXPLORATORY OBJECTIVES:

I. To evaluate the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL across different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years).

II. To bank specimens for future correlative studies. III. To assess concordance and discordance of rapid central review and local institutional review of FDG PET 5-point score (5-PS; previously referred to as Deauville score) at baseline PET1, interim PET2 and end of systemic therapy PET-end of systemic therapy (EST) SER.

IV. To assess the association between PFS and the quantitative FDG-PET/computed tomography (CT) parameters (PET MTV, TLG, delta-standardized uptake value [SUV] and PET SUV-based quantitative surrogates [qPET] of visual qualitative 5-PS) on measurements by automated measurements using convolutional neural networks (CNNs) through artificial-intelligence (AI) machine learning in the entire population.

V. To assess the agreement between quantitative FDG-PET/CT parameters obtained using AI and those based on measurements by a trained imaging physician.

VI. To compare patient-reported adverse events (via pediatric [Ped]-PRO-CTCAE and PRO-CTCAE) to provider adverse event reporting.

VII. To evaluate the association between self-reported race/ethnicity and social determinants of health.

VIII. To evaluate the associations between race/ethnicity and post-progression/post-relapse overall survival.

IX. To evaluate the completion rates of PRO and health-related quality of life (HRQoL) contact forms at 1 year off treatment for the first 450 eligible patients.

X. To collect contact information from participants for future re-contact.

OUTLINE: Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride intravenously [IV] over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or magnetic resonance imaging (MRI) and are identified as RER or SER.

Patients with a favorable risk status and RER are randomized to Arm A or Arm B. Patients with a favorable risk status and SER are randomized to Arm C or Arm D. Patients with an unfavorable risk status and RER are randomized to Arm E or Arm F. Patients with an unfavorable risk status and SER are randomized to Arm G or Arm H.

ARM A (RER, FAVORABLE): Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM B (RER, FAVORABLE): Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM C (SER, FAVORABLE): Patients receive either the eBEACOPP regimen (doxorubicin hydrochloride IV over 3-15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone orally [PO] twice daily [BID] on days 1-14, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV over at least 10 minutes on day 8, and vincristine sulfate IV on day 8 of each cycle) or the eBPDac regimen (doxorubicin hydrochloride IV 3-15 minutes on day 1, cyclophosphamide IV 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone PO BID on days 1-14, dacarbazine IV over 15-60 minutes on days 2 & 3, bleomycin sulfate IV over at least 10 minutes on day 4, 5, 6, 7, or 8, vincristine sulfate IV on day 4, 5, 6, 7, or 8 of each cycle). Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM D (SER, FAVORABLE): Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM E (RER, UNFAVORABLE): Patients receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM F (RER, UNFAVORABLE): Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM G (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.

ARM H (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.

After completion of study treatment, patients are followed up every 3 months for the first year, then every 6 months for the second and third year, then annually until 12 years from date of registration.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1875

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Québec, Canada, G1V 4G2
        • Reclutamento
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • Investigatore principale:
          • Bruno Michon
        • Contatto:
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Reclutamento
        • Alberta Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Victor A. Lewis
      • Edmonton, Alberta, Canada, T6G 2B7
        • Reclutamento
        • University of Alberta Hospital
        • Contatto:
        • Investigatore principale:
          • Sarah J. McKillop
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • Reclutamento
        • British Columbia Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 6477 604-875-2345
        • Investigatore principale:
          • Rebecca J. Deyell
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Reclutamento
        • CancerCare Manitoba
        • Contatto:
        • Investigatore principale:
          • Stephanie M. Villeneuve
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Reclutamento
        • IWK Health Centre
        • Contatto:
        • Investigatore principale:
          • Chelsea Ash
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Reclutamento
        • McMaster Children's Hospital at Hamilton Health Sciences
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 905-521-2100
        • Investigatore principale:
          • Uma H. Athale
      • London, Ontario, Canada, N6A 5W9
        • Reclutamento
        • Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 519-685-8306
        • Investigatore principale:
          • Shayna M. Zelcer
      • Ottawa, Ontario, Canada, K1H 8L1
        • Reclutamento
        • Children's Hospital of Eastern Ontario
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 613-737-7600
        • Investigatore principale:
          • Donna L. Johnston
      • Toronto, Ontario, Canada, M5G 1X8
        • Reclutamento
        • Hospital for Sick Children
        • Contatto:
        • Investigatore principale:
          • Angela S. Punnett
    • Quebec
      • Montreal, Quebec, Canada, H3H 1P3
        • Reclutamento
        • The Montreal Children's Hospital of the MUHC
        • Contatto:
        • Investigatore principale:
          • Stephanie Mourad
      • Montreal, Quebec, Canada, H3T 1C5
        • Reclutamento
        • Centre Hospitalier Universitaire Sainte-Justine
        • Investigatore principale:
          • Monia Marzouki
        • Contatto:
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Reclutamento
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • Contatto:
        • Investigatore principale:
          • Stephanie Vairy
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Reclutamento
        • Jim Pattison Children's Hospital
        • Investigatore principale:
          • Kathleen Felton
        • Contatto:
      • San Juan, Porto Rico, 00926
        • Reclutamento
        • University Pediatric Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 787-474-0333
        • Investigatore principale:
          • Maria E. Echevarria
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Reclutamento
        • Children's Hospital of Alabama
        • Investigatore principale:
          • Ana C. Xavier
        • Contatto:
      • Mobile, Alabama, Stati Uniti, 36604
        • Reclutamento
        • USA Health Strada Patient Care Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-388-8721
        • Investigatore principale:
          • Hamayun Imran
    • Alaska
      • Anchorage, Alaska, Stati Uniti, 99508
    • Arizona
      • Goodyear, Arizona, Stati Uniti, 85338
        • Reclutamento
        • CTCA at Western Regional Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 623-207-3000
        • Investigatore principale:
          • Sarah Monick
      • Mesa, Arizona, Stati Uniti, 85202
        • Reclutamento
        • Banner Children's at Desert
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 480-412-3100
        • Investigatore principale:
          • Joseph C. Torkildson
      • Phoenix, Arizona, Stati Uniti, 85016
        • Reclutamento
        • Phoenix Childrens Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 602-546-0920
        • Investigatore principale:
          • Alexandra M. Walsh
      • Phoenix, Arizona, Stati Uniti, 85004
    • Arkansas
      • Little Rock, Arkansas, Stati Uniti, 72202-3591
        • Reclutamento
        • Arkansas Children's Hospital
        • Investigatore principale:
          • Michael W. Bishop
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 501-364-7373
    • California
      • Carmichael, California, Stati Uniti, 95608
      • Carmichael, California, Stati Uniti, 95608
      • Corona, California, Stati Uniti, 92882
        • Reclutamento
        • City of Hope Corona
        • Investigatore principale:
          • Alex F. Herrera
        • Contatto:
      • Costa Mesa, California, Stati Uniti, 92627
        • Reclutamento
        • UC Irvine Health Cancer Center-Newport
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-827-8839
        • Investigatore principale:
          • Nicole Foley
      • Downey, California, Stati Uniti, 90242
        • Reclutamento
        • Kaiser Permanente Downey Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 626-564-3455
        • Investigatore principale:
          • Robert M. Cooper
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Alex F. Herrera
      • Dublin, California, Stati Uniti, 94568
        • Reclutamento
        • Kaiser Permanente Dublin
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
        • Investigatore principale:
          • Sachdev P. Thomas
      • Elk Grove, California, Stati Uniti, 95758
      • Fremont, California, Stati Uniti, 94538
        • Reclutamento
        • Kaiser Permanente-Fremont
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Fresno, California, Stati Uniti, 93720
        • Reclutamento
        • Kaiser Permanente-Fresno
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Fresno, California, Stati Uniti, 93720
        • Sospeso
        • Kaiser Permanente Fresno Orchard Plaza
      • Huntington Beach, California, Stati Uniti, 92648
        • Reclutamento
        • City of Hope Seacliff
        • Investigatore principale:
          • Alex F. Herrera
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 626-256-4673
      • Irvine, California, Stati Uniti, 92618
        • Reclutamento
        • City of Hope at Irvine Lennar
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-467-3411
        • Investigatore principale:
          • Alex F. Herrera
      • Irvine, California, Stati Uniti, 92612
        • Reclutamento
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-827-8839
          • Email: ucstudy@uci.edu
        • Investigatore principale:
          • Nicole Foley
      • Lancaster, California, Stati Uniti, 93534
        • Reclutamento
        • City of Hope Antelope Valley
        • Contatto:
        • Investigatore principale:
          • Alex F. Herrera
      • Loma Linda, California, Stati Uniti, 92354
        • Reclutamento
        • Loma Linda University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 909-558-4050
        • Investigatore principale:
          • Albert Kheradpour
      • Long Beach, California, Stati Uniti, 90806
        • Reclutamento
        • Miller Children's and Women's Hospital Long Beach
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 562-933-5600
        • Investigatore principale:
          • Jacqueline N. Casillas
      • Long Beach, California, Stati Uniti, 90813
        • Reclutamento
        • City of Hope at Long Beach Elm
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-467-3411
        • Investigatore principale:
          • Alex F. Herrera
      • Los Angeles, California, Stati Uniti, 90027
        • Reclutamento
        • Children's Hospital Los Angeles
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 323-361-4110
        • Investigatore principale:
          • Andrew Doan
      • Los Angeles, California, Stati Uniti, 90048
        • Reclutamento
        • Cedars-Sinai Medical Center
        • Investigatore principale:
          • Nicole M. Baca
        • Contatto:
      • Madera, California, Stati Uniti, 93636
        • Reclutamento
        • Valley Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Ruetima Titapiwatanakun
      • Modesto, California, Stati Uniti, 95356
        • Reclutamento
        • Kaiser Permanente-Modesto
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Modesto, California, Stati Uniti, 95356
        • Sospeso
        • Kaiser Permanente- Modesto MOB II
      • Newport Beach, California, Stati Uniti, 92660
        • Reclutamento
        • City of Hope Newport Beach
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-467-3411
        • Investigatore principale:
          • Alex F. Herrera
      • Oakland, California, Stati Uniti, 94611
        • Reclutamento
        • Kaiser Permanente-Oakland
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Aarati V. Rao
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • Children's Hospital of Orange County
        • Contatto:
        • Investigatore principale:
          • Elyssa M. Rubin
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-827-8839
          • Email: ucstudy@uci.edu
        • Investigatore principale:
          • Nicole Foley
      • Rocklin, California, Stati Uniti, 95765
      • Sacramento, California, Stati Uniti, 95814
        • Reclutamento
        • Kaiser Permanente Downtown Commons
        • Investigatore principale:
          • Sachdev P. Thomas
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: kpoct@kp.org
      • Sacramento, California, Stati Uniti, 95816
      • Sacramento, California, Stati Uniti, 95823
        • Reclutamento
        • Kaiser Permanente-South Sacramento
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Sacramento, California, Stati Uniti, 95816
      • San Diego, California, Stati Uniti, 92123
        • Reclutamento
        • Rady Children's Hospital - San Diego
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 858-966-5934
        • Investigatore principale:
          • William D. Roberts
      • San Diego, California, Stati Uniti, 92134
        • Reclutamento
        • Naval Medical Center -San Diego
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 619-532-8712
        • Investigatore principale:
          • Yoko T. Udaka
      • San Francisco, California, Stati Uniti, 94115
        • Reclutamento
        • Kaiser Permanente-San Francisco
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • San Jose, California, Stati Uniti, 95119
        • Reclutamento
        • Kaiser Permanente-Santa Teresa-San Jose
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • San Leandro, California, Stati Uniti, 94577
        • Reclutamento
        • Kaiser Permanente San Leandro
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • San Rafael, California, Stati Uniti, 94903
        • Reclutamento
        • Kaiser San Rafael-Gallinas
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Santa Barbara, California, Stati Uniti, 93102
        • Reclutamento
        • Santa Barbara Cottage Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 805-682-7300
        • Investigatore principale:
          • Shivani Upadhyay
      • Santa Rosa, California, Stati Uniti, 95403
        • Reclutamento
        • Kaiser Permanente-Santa Rosa
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • South Pasadena, California, Stati Uniti, 91030
        • Reclutamento
        • City of Hope South Pasadena
        • Contatto:
        • Investigatore principale:
          • Alex F. Herrera
      • South San Francisco, California, Stati Uniti, 94080
        • Reclutamento
        • Kaiser Permanente-South San Francisco
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Torrance, California, Stati Uniti, 90503
        • Reclutamento
        • City of Hope South Bay
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-467-3411
        • Investigatore principale:
          • Alex F. Herrera
      • Upland, California, Stati Uniti, 91786
        • Reclutamento
        • City of Hope Upland
        • Contatto:
        • Investigatore principale:
          • Alex F. Herrera
      • Vallejo, California, Stati Uniti, 94589
        • Reclutamento
        • Kaiser Permanente-Vallejo
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Walnut Creek, California, Stati Uniti, 94596
        • Reclutamento
        • Kaiser Permanente-Walnut Creek
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-642-4691
          • Email: Kpoct@kp.org
        • Investigatore principale:
          • Sachdev P. Thomas
      • Woodland, California, Stati Uniti, 95695
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • Children's Hospital Colorado
        • Contatto:
        • Investigatore principale:
          • Kelly W. Maloney
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • UCHealth University of Colorado Hospital
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 720-848-0650
      • Colorado Springs, Colorado, Stati Uniti, 80909
        • Reclutamento
        • UCHealth Memorial Hospital Central
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 719-365-2406
      • Colorado Springs, Colorado, Stati Uniti, 80920
        • Reclutamento
        • Memorial Hospital North
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 719-364-6700
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
        • Contatto:
        • Investigatore principale:
          • Florence Choo
      • Fort Collins, Colorado, Stati Uniti, 80524
        • Reclutamento
        • Poudre Valley Hospital
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 970-297-6150
      • Fort Collins, Colorado, Stati Uniti, 80528
        • Reclutamento
        • Cancer Care and Hematology-Fort Collins
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
      • Greeley, Colorado, Stati Uniti, 80631
        • Reclutamento
        • UCHealth Greeley Hospital
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
      • Loveland, Colorado, Stati Uniti, 80538
        • Reclutamento
        • Medical Center of the Rockies
        • Investigatore principale:
          • Sarah Milgrom
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 970-203-7083
    • Connecticut
      • Derby, Connecticut, Stati Uniti, 06418
        • Reclutamento
        • Smilow Cancer Hospital-Derby Care Center
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Fairfield, Connecticut, Stati Uniti, 06824
        • Reclutamento
        • Smilow Cancer Hospital Care Center-Fairfield
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Glastonbury, Connecticut, Stati Uniti, 06033
        • Reclutamento
        • Smilow Cancer Hospital Care Center at Glastonbury
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Greenwich, Connecticut, Stati Uniti, 06830
        • Reclutamento
        • Smilow Cancer Hospital Care Center at Greenwich
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Guilford, Connecticut, Stati Uniti, 06437
        • Reclutamento
        • Smilow Cancer Hospital Care Center - Guilford
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Hartford, Connecticut, Stati Uniti, 06106
        • Reclutamento
        • Connecticut Children's Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 860-545-9981
        • Investigatore principale:
          • Michael S. Isakoff
      • Hartford, Connecticut, Stati Uniti, 06105
        • Reclutamento
        • Smilow Cancer Hospital Care Center at Saint Francis
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • New Haven, Connecticut, Stati Uniti, 06520
        • Reclutamento
        • Yale University
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • North Haven, Connecticut, Stati Uniti, 06473
        • Reclutamento
        • Yale-New Haven Hospital North Haven Medical Center
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Stamford, Connecticut, Stati Uniti, 06902
        • Reclutamento
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Torrington, Connecticut, Stati Uniti, 06790
        • Reclutamento
        • Smilow Cancer Hospital-Torrington Care Center
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Trumbull, Connecticut, Stati Uniti, 06611
        • Reclutamento
        • Smilow Cancer Hospital Care Center-Trumbull
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Waterbury, Connecticut, Stati Uniti, 06708
        • Reclutamento
        • Smilow Cancer Hospital-Waterbury Care Center
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
      • Waterford, Connecticut, Stati Uniti, 06385
        • Reclutamento
        • Smilow Cancer Hospital Care Center - Waterford
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
    • Delaware
      • Wilmington, Delaware, Stati Uniti, 19803
        • Reclutamento
        • Alfred I duPont Hospital for Children
        • Contatto:
        • Investigatore principale:
          • Vibhuti Agarwal
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • Children's National Medical Center
        • Investigatore principale:
          • Jeffrey S. Dome
        • Contatto:
      • Washington D.C., District of Columbia, Stati Uniti, 20007
        • Reclutamento
        • MedStar Georgetown University Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 202-444-2223
        • Investigatore principale:
          • Caileigh Pudela
    • Florida
      • Fort Lauderdale, Florida, Stati Uniti, 33316
        • Reclutamento
        • Broward Health Medical Center
        • Contatto:
        • Investigatore principale:
          • Hector M. Rodriguez-Cortes
      • Fort Myers, Florida, Stati Uniti, 33908
        • Reclutamento
        • Golisano Children's Hospital of Southwest Florida
        • Contatto:
        • Investigatore principale:
          • Emad K. Salman
      • Gainesville, Florida, Stati Uniti, 32610
        • Reclutamento
        • UF Health Cancer Institute - Gainesville
        • Investigatore principale:
          • Brian Stover
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 352-273-8010
      • Hollywood, Florida, Stati Uniti, 33021
        • Reclutamento
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 954-265-1847
          • Email: OHR@mhs.net
        • Investigatore principale:
          • Iftikhar Hanif
      • Jacksonville, Florida, Stati Uniti, 32207
        • Reclutamento
        • Nemours Children's Clinic-Jacksonville
        • Contatto:
        • Investigatore principale:
          • Vibhuti Agarwal
      • Jacksonville, Florida, Stati Uniti, 32224-9980
        • Reclutamento
        • Mayo Clinic in Florida
        • Investigatore principale:
          • Mira Kohorst
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 855-776-0015
      • Miami, Florida, Stati Uniti, 33155
        • Reclutamento
        • Nicklaus Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-624-2778
        • Investigatore principale:
          • Ziad A. Khatib
      • Miami, Florida, Stati Uniti, 33136
        • Sospeso
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami Beach, Florida, Stati Uniti, 33140
        • Reclutamento
        • Mount Sinai Medical Center
        • Contatto:
        • Investigatore principale:
          • Jacqueline C. Barrientos
      • Orlando, Florida, Stati Uniti, 32806
        • Reclutamento
        • Arnold Palmer Hospital for Children
        • Contatto:
        • Investigatore principale:
          • Zhongbo Hu
      • Orlando, Florida, Stati Uniti, 32827
        • Reclutamento
        • Nemours Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Vibhuti Agarwal
      • Orlando, Florida, Stati Uniti, 32803
        • Reclutamento
        • AdventHealth Orlando
        • Contatto:
        • Investigatore principale:
          • Fouad M. Hajjar
      • Pensacola, Florida, Stati Uniti, 32504
        • Sospeso
        • Sacred Heart Hospital
      • Pensacola, Florida, Stati Uniti, 32504
      • St. Petersburg, Florida, Stati Uniti, 33701
        • Reclutamento
        • Johns Hopkins All Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Jennifer B. Dean
      • Tampa, Florida, Stati Uniti, 33606
        • Reclutamento
        • Tampa General Hospital
        • Contatto:
        • Investigatore principale:
          • Andrew J. Galligan
      • Tampa, Florida, Stati Uniti, 33607
        • Reclutamento
        • Saint Joseph's Hospital/Children's Hospital-Tampa
        • Contatto:
        • Investigatore principale:
          • Don E. Eslin
      • West Palm Beach, Florida, Stati Uniti, 33407
        • Reclutamento
        • Saint Mary's Medical Center
        • Investigatore principale:
          • Matthew D. Ramirez
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 561-822-4745
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital/Winship Cancer Institute
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-778-1868
        • Investigatore principale:
          • Pamela B. Allen
      • Atlanta, Georgia, Stati Uniti, 30303
        • Reclutamento
        • Grady Health System
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-778-1868
        • Investigatore principale:
          • Pamela B. Allen
      • Atlanta, Georgia, Stati Uniti, 30308
        • Reclutamento
        • Emory University Hospital Midtown
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-946-7447
        • Investigatore principale:
          • Pamela B. Allen
      • Atlanta, Georgia, Stati Uniti, 30342
        • Reclutamento
        • Emory Saint Joseph's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 404-851-7115
        • Investigatore principale:
          • Pamela B. Allen
      • Atlanta, Georgia, Stati Uniti, 30308
        • Reclutamento
        • Emory Proton Therapy Center
        • Contatto:
        • Investigatore principale:
          • Pamela B. Allen
      • Atlanta, Georgia, Stati Uniti, 30329
        • Reclutamento
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • Investigatore principale:
          • Diana Fridlyand
        • Contatto:
      • Augusta, Georgia, Stati Uniti, 30912
        • Reclutamento
        • Augusta University Medical Center
        • Contatto:
        • Investigatore principale:
          • Colleen H. McDonough
      • Macon, Georgia, Stati Uniti, 31201
        • Reclutamento
        • Atrium Health Navicent
        • Investigatore principale:
          • Sushmita Nair
        • Contatto:
      • Savannah, Georgia, Stati Uniti, 31404
        • Reclutamento
        • Memorial Health University Medical Center
        • Contatto:
        • Investigatore principale:
          • James N. Yarnall
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96826
        • Reclutamento
        • Kapiolani Medical Center for Women and Children
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 808-983-6090
        • Investigatore principale:
          • Wade T. Kyono
    • Idaho
      • Boise, Idaho, Stati Uniti, 83712
        • Reclutamento
        • Saint Luke's Cancer Institute - Boise
        • Investigatore principale:
          • Martha M. Pacheco
        • Contatto:
      • Boise, Idaho, Stati Uniti, 83706
        • Reclutamento
        • Saint Alphonsus Cancer Care Center-Boise
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Caldwell, Idaho, Stati Uniti, 83605
        • Reclutamento
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Fruitland, Idaho, Stati Uniti, 83619
        • Reclutamento
        • Saint Luke's Cancer Institute - Fruitland
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Meridian, Idaho, Stati Uniti, 83642
        • Reclutamento
        • Idaho Urologic Institute-Meridian
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Meridian, Idaho, Stati Uniti, 83642
        • Reclutamento
        • Saint Luke's Cancer Institute - Meridian
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Nampa, Idaho, Stati Uniti, 83687
        • Reclutamento
        • Saint Luke's Cancer Institute - Nampa
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Nampa, Idaho, Stati Uniti, 83687
        • Reclutamento
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Twin Falls, Idaho, Stati Uniti, 83301
        • Reclutamento
        • Saint Luke's Cancer Institute - Twin Falls
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
    • Illinois
      • Aurora, Illinois, Stati Uniti, 60504
        • Reclutamento
        • Rush-Copley Medical Center
        • Contatto:
        • Investigatore principale:
          • Joseph T. Meschi
      • Barrington, Illinois, Stati Uniti, 60010
        • Reclutamento
        • Advocate Good Shepherd Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-842-4847
        • Investigatore principale:
          • Rebecca E. McFall
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Lurie Children's Hospital-Chicago
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 773-880-4562
        • Investigatore principale:
          • Joanna L. Weinstein
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Perry C. Morocco
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
        • Investigatore principale:
          • Jane N. Winter
        • Contatto:
      • Chicago, Illinois, Stati Uniti, 60612
        • Reclutamento
        • University of Illinois
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 312-355-3046
        • Investigatore principale:
          • Dipti S. Dighe
      • Chicago, Illinois, Stati Uniti, 60657
        • Reclutamento
        • Advocate Illinois Masonic Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 773-296-5360
        • Investigatore principale:
          • Rebecca E. McFall
      • Chicago, Illinois, Stati Uniti, 60608
        • Reclutamento
        • Mount Sinai Hospital Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 773-257-5960
          • Email: suhi@sinai.org
        • Investigatore principale:
          • Pam G. Khosla
      • Chicago, Illinois, Stati Uniti, 60625
        • Reclutamento
        • Swedish Covenant Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 773-878-8200
        • Investigatore principale:
          • Robert M. Eisner
      • Crystal Lake, Illinois, Stati Uniti, 60014
        • Reclutamento
        • AMG Crystal Lake - Oncology
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Danville, Illinois, Stati Uniti, 61832
        • Reclutamento
        • Carle at The Riverfront
        • Investigatore principale:
          • Priyank P. Patel
        • Contatto:
      • DeKalb, Illinois, Stati Uniti, 60115
        • Reclutamento
        • Northwestern Medicine Cancer Center Kishwaukee
        • Investigatore principale:
          • Jane N. Winter
        • Contatto:
      • Decatur, Illinois, Stati Uniti, 62526
        • Reclutamento
        • Decatur Memorial Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Downers Grove, Illinois, Stati Uniti, 60515
        • Reclutamento
        • Advocate Good Samaritan Hospital
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Effingham, Illinois, Stati Uniti, 62401
        • Reclutamento
        • Carle Physician Group-Effingham
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
      • Effingham, Illinois, Stati Uniti, 62401
        • Reclutamento
        • Crossroads Cancer Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Elgin, Illinois, Stati Uniti, 60123
        • Reclutamento
        • Advocate Sherman Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-429-2907
        • Investigatore principale:
          • Rebecca E. McFall
      • Elmhurst, Illinois, Stati Uniti, 60126
        • Reclutamento
        • Elmhurst Memorial Hospital
        • Investigatore principale:
          • Joseph Heng
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 630-758-5460
          • Email: Jrohde@emhc.org
      • Evanston, Illinois, Stati Uniti, 60201
        • Reclutamento
        • NorthShore University HealthSystem-Evanston Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Robert M. Eisner
      • Geneva, Illinois, Stati Uniti, 60134
        • Reclutamento
        • Northwestern Medicine Cancer Center Delnor
        • Investigatore principale:
          • Jane N. Winter
        • Contatto:
      • Glenview, Illinois, Stati Uniti, 60026
        • Reclutamento
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Robert M. Eisner
      • Glenview, Illinois, Stati Uniti, 60026
        • Attivo, non reclutante
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, Stati Uniti, 60030
        • Attivo, non reclutante
        • Northwestern Medicine Grayslake Outpatient Center
      • Hazel Crest, Illinois, Stati Uniti, 60429
        • Reclutamento
        • Advocate South Suburban Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 708-799-9995
        • Investigatore principale:
          • Rebecca E. McFall
      • Highland Park, Illinois, Stati Uniti, 60035
        • Reclutamento
        • NorthShore University HealthSystem-Highland Park Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-570-2109
        • Investigatore principale:
          • Robert M. Eisner
      • Lake Forest, Illinois, Stati Uniti, 60045
        • Attivo, non reclutante
        • Northwestern Medicine Lake Forest Hospital
      • Libertyville, Illinois, Stati Uniti, 60048
        • Reclutamento
        • AMG Libertyville - Oncology
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Libertyville, Illinois, Stati Uniti, 60048
        • Reclutamento
        • Condell Memorial Hospital
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Mattoon, Illinois, Stati Uniti, 61938
        • Reclutamento
        • Carle Physician Group-Mattoon/Charleston
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
      • Maywood, Illinois, Stati Uniti, 60153
        • Reclutamento
        • Loyola University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 708-226-4357
        • Investigatore principale:
          • Eugene Suh
      • Naperville, Illinois, Stati Uniti, 60540
        • Reclutamento
        • Edward Hospital/Cancer Center
        • Investigatore principale:
          • Joseph Heng
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 630-646-6075
      • O'Fallon, Illinois, Stati Uniti, 62269
        • Reclutamento
        • HSHS Saint Elizabeth's Hospital
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
      • Oak Lawn, Illinois, Stati Uniti, 60453-2699
        • Reclutamento
        • Advocate Christ Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-323-8622
        • Investigatore principale:
          • Rebecca E. McFall
      • Oak Lawn, Illinois, Stati Uniti, 60453
        • Reclutamento
        • Advocate Children's Hospital-Oak Lawn
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-723-7570
        • Investigatore principale:
          • Rebecca E. McFall
      • Orland Park, Illinois, Stati Uniti, 60462
      • Park Ridge, Illinois, Stati Uniti, 60068
        • Reclutamento
        • Advocate Lutheran General Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 847-384-3621
        • Investigatore principale:
          • Rebecca E. McFall
      • Park Ridge, Illinois, Stati Uniti, 60068
      • Peoria, Illinois, Stati Uniti, 61637
      • Plainfield, Illinois, Stati Uniti, 60585
        • Reclutamento
        • Edward Hospital/Cancer Center?Plainfield
        • Investigatore principale:
          • Joseph Heng
        • Contatto:
      • Rockford, Illinois, Stati Uniti, 61114
        • Reclutamento
        • UW Health Carbone Cancer Center Rockford
        • Contatto:
        • Investigatore principale:
          • Fahrettin Covut
      • Shiloh, Illinois, Stati Uniti, 62269
        • Reclutamento
        • Memorial Hospital East
        • Contatto:
        • Investigatore principale:
          • Nancy L. Bartlett
      • Springfield, Illinois, Stati Uniti, 62702
        • Reclutamento
        • Southern Illinois University School of Medicine
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 217-545-7929
        • Investigatore principale:
          • Gregory P. Brandt
      • Urbana, Illinois, Stati Uniti, 61801
        • Reclutamento
        • Carle Cancer Center
        • Contatto:
        • Investigatore principale:
          • Priyank P. Patel
      • Warrenville, Illinois, Stati Uniti, 60555
        • Reclutamento
        • Northwestern Medicine Cancer Center Warrenville
        • Investigatore principale:
          • Jane N. Winter
        • Contatto:
      • Yorkville, Illinois, Stati Uniti, 60560
        • Sospeso
        • Rush-Copley Healthcare Center
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Reclutamento
        • Riley Hospital for Children
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-248-1199
        • Investigatore principale:
          • Jennifer A. Belsky
      • Indianapolis, Indiana, Stati Uniti, 46260
        • Reclutamento
        • Ascension Saint Vincent Indianapolis Hospital
        • Contatto:
        • Investigatore principale:
          • Bassem I. Razzouk
    • Iowa
      • Ankeny, Iowa, Stati Uniti, 50023
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Carroll, Iowa, Stati Uniti, 51401
        • Reclutamento
        • Saint Anthony Regional Hospital
        • Contatto:
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Clive, Iowa, Stati Uniti, 50325
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50309
        • Reclutamento
        • Blank Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Samantha L. Mallory
      • Des Moines, Iowa, Stati Uniti, 50309
        • Reclutamento
        • Iowa Methodist Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-6727
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50309
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Stati Uniti, 50314
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa/Holden Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-237-1225
        • Investigatore principale:
          • Andrew P. Groves
      • Waukee, Iowa, Stati Uniti, 50263
        • Reclutamento
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 515-241-3305
        • Investigatore principale:
          • Seema Harichand-Herdt
    • Kansas
      • Wichita, Kansas, Stati Uniti, 67214
        • Reclutamento
        • Wesley Medical Center
        • Contatto:
        • Investigatore principale:
          • Nathan S. Hall
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky/Markey Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 859-257-3379
        • Investigatore principale:
          • James T. Badgett
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • Norton Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Michael J. Ferguson
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • The James Graham Brown Cancer Center at University of Louisville
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 502-562-3429
        • Investigatore principale:
          • Hassaan Yasin
      • Louisville, Kentucky, Stati Uniti, 40245
        • Reclutamento
        • UofL Health Medical Center Northeast
        • Contatto:
        • Investigatore principale:
          • Hassaan Yasin
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70118
        • Reclutamento
        • Children's Hospital New Orleans
        • Investigatore principale:
          • Maria C. Velez-Yanguas
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 504-894-5377
      • New Orleans, Louisiana, Stati Uniti, 70121
        • Reclutamento
        • Ochsner Medical Center Jefferson
        • Contatto:
        • Investigatore principale:
          • Craig Lotterman
    • Maine
      • Bangor, Maine, Stati Uniti, 04401
        • Reclutamento
        • Eastern Maine Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 207-973-4274
        • Investigatore principale:
          • Daniel L. Callaway
      • Bath, Maine, Stati Uniti, 04530
        • Reclutamento
        • MaineHealth Coastal Cancer Treatment Center
        • Contatto:
        • Investigatore principale:
          • Nadav L. Kastle
      • Portland, Maine, Stati Uniti, 04102
        • Reclutamento
        • MaineHealth Maine Medical Center - Portland
        • Investigatore principale:
          • Nadav L. Kastle
        • Contatto:
      • Sanford, Maine, Stati Uniti, 04073
        • Reclutamento
        • MaineHealth Cancer Care Center of York County
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 207-459-1600
        • Investigatore principale:
          • Nadav L. Kastle
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • Maine Children's Cancer Program
        • Investigatore principale:
          • Nadav L. Kastle
        • Contatto:
      • Scarborough, Maine, Stati Uniti, 04074
        • Reclutamento
        • MaineHealth Maine Medical Center- Scarborough
        • Investigatore principale:
          • Nadav L. Kastle
        • Contatto:
      • South Portland, Maine, Stati Uniti, 04106
        • Reclutamento
        • MaineHealth Cancer Care and IV Therapy - South Portland
        • Investigatore principale:
          • Nadav L. Kastle
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Reclutamento
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Investigatore principale:
          • Stacy L. Cooper
        • Contatto:
      • Baltimore, Maryland, Stati Uniti, 21215
        • Reclutamento
        • Sinai Hospital of Baltimore
        • Investigatore principale:
          • Jason M. Fixler
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 410-601-9083
      • Baltimore, Maryland, Stati Uniti, 21201
        • Reclutamento
        • University of Maryland/Greenebaum Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-888-8823
        • Investigatore principale:
          • Teresa A. York
      • Bethesda, Maryland, Stati Uniti, 20889-5600
        • Reclutamento
        • Walter Reed National Military Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 301-319-2100
        • Investigatore principale:
          • Kip R. Hartman
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana-Farber Cancer Institute
        • Investigatore principale:
          • Ann S. LaCasce
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 877-442-3324
      • Worcester, Massachusetts, Stati Uniti, 01655
        • Reclutamento
        • UMass Memorial Medical Center - University Campus
        • Contatto:
        • Investigatore principale:
          • Stefanie R. Lowas
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • C S Mott Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-865-1125
        • Investigatore principale:
          • Emily B. Walling
      • Ann Arbor, Michigan, Stati Uniti, 48106
        • Reclutamento
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Battle Creek, Michigan, Stati Uniti, 49017
        • Reclutamento
        • Bronson Battle Creek
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Brighton, Michigan, Stati Uniti, 48114
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Brownstown, Michigan, Stati Uniti, 48183
        • Reclutamento
        • Henry Ford Cancer Institute-Downriver
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Canton, Michigan, Stati Uniti, 48188
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Chelsea, Michigan, Stati Uniti, 48118
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Clinton Township, Michigan, Stati Uniti, 48038
        • Reclutamento
        • Henry Ford Macomb Hospital-Clinton Township
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Dearborn, Michigan, Stati Uniti, 48126
        • Reclutamento
        • Henry Ford Medical Center-Fairlane
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Dearborn, Michigan, Stati Uniti, 48124
        • Reclutamento
        • Corewell Health Dearborn Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 248-551-7695
        • Investigatore principale:
          • Marie V. Nelson
      • Detroit, Michigan, Stati Uniti, 48201
        • Reclutamento
        • Wayne State University/Karmanos Cancer Institute
        • Investigatore principale:
          • Vijendra Singh
        • Contatto:
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Hospital
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Detroit, Michigan, Stati Uniti, 48201
      • East Lansing, Michigan, Stati Uniti, 48823
        • Attivo, non reclutante
        • Michigan State University
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Reclutamento
        • Weisberg Cancer Treatment Center
        • Contatto:
        • Investigatore principale:
          • Vijendra Singh
      • Farmington Hills, Michigan, Stati Uniti, 48336
        • Reclutamento
        • Corewell Health Farmington Hills Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 248-551-7695
        • Investigatore principale:
          • Marie V. Nelson
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Trinity Health Grand Rapids Hospital
        • Investigatore principale:
          • Christopher M. Reynolds
        • Contatto:
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Reclutamento
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Jackson, Michigan, Stati Uniti, 49201
        • Reclutamento
        • Allegiance Health
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • Reclutamento
        • Bronson Methodist Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Stati Uniti, 49007
        • Reclutamento
        • West Michigan Cancer Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Stati Uniti, 49009
        • Reclutamento
        • Beacon Kalamazoo Cancer Center
        • Investigatore principale:
          • Kathleen Y. Butler
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 574-647-7370
      • Livonia, Michigan, Stati Uniti, 48154
        • Reclutamento
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Macomb, Michigan, Stati Uniti, 48044
        • Reclutamento
        • Henry Ford Saint John Hospital - Macomb Medical
        • Investigatore principale:
          • Christopher M. Reynolds
        • Contatto:
      • Muskegon, Michigan, Stati Uniti, 49444
        • Sospeso
        • Trinity Health Muskegon Hospital
      • Norton Shores, Michigan, Stati Uniti, 49444
        • Reclutamento
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
        • Investigatore principale:
          • Christopher M. Reynolds
        • Contatto:
      • Novi, Michigan, Stati Uniti, 48377
        • Reclutamento
        • Henry Ford Medical Center-Columbus
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Novi, Michigan, Stati Uniti, 48374
        • Sospeso
        • Henry Ford Health Providence Novi Hospital
      • Pontiac, Michigan, Stati Uniti, 48341
        • Reclutamento
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Reed City, Michigan, Stati Uniti, 49677
        • Reclutamento
        • Corewell Health Reed City Hospital
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, Stati Uniti, 48073
        • Reclutamento
        • Corewell Health William Beaumont University Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 248-551-7695
        • Investigatore principale:
          • Marie V. Nelson
      • Royal Oak, Michigan, Stati Uniti, 48073
        • Reclutamento
        • Corewell Health Children's
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 248-551-7695
        • Investigatore principale:
          • Marie V. Nelson
      • Saint Joseph, Michigan, Stati Uniti, 49085
        • Reclutamento
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Southfield, Michigan, Stati Uniti, 48075
        • Sospeso
        • Henry Ford Health Providence Southfield Hospital
      • Traverse City, Michigan, Stati Uniti, 49684
        • Reclutamento
        • Munson Medical Center
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Troy, Michigan, Stati Uniti, 48085
        • Reclutamento
        • Corewell Health Beaumont Troy Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 248-551-7695
        • Investigatore principale:
          • Marie V. Nelson
      • West Bloomfield, Michigan, Stati Uniti, 48322
        • Reclutamento
        • Henry Ford West Bloomfield Hospital
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Wyandotte, Michigan, Stati Uniti, 48192
        • Reclutamento
        • Henry Ford Wyandotte Hospital
        • Contatto:
        • Investigatore principale:
          • Philip Kuriakose
      • Wyoming, Michigan, Stati Uniti, 49519
        • Reclutamento
        • University of Michigan Health - West
        • Contatto:
        • Investigatore principale:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, Stati Uniti, 48197
        • Reclutamento
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
    • Minnesota
      • Coon Rapids, Minnesota, Stati Uniti, 55433
        • Reclutamento
        • Mercy Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Fairview Southdale Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Edina, Minnesota, Stati Uniti, 55435
        • Reclutamento
        • Minnesota Oncology - Edina
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Minneapolis, Minnesota, Stati Uniti, 55404
        • Reclutamento
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • Investigatore principale:
          • Michael K. Richards
        • Contatto:
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Reclutamento
        • Abbott-Northwestern Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Reclutamento
        • University of Minnesota/Masonic Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 612-624-2620
        • Investigatore principale:
          • Peter M. Gordon
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic in Rochester
        • Investigatore principale:
          • Mira Kohorst
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 855-776-0015
      • Saint Louis Park, Minnesota, Stati Uniti, 55416
        • Reclutamento
        • Park Nicollet Clinic - Saint Louis Park
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Saint Paul, Minnesota, Stati Uniti, 55101
        • Reclutamento
        • Regions Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Saint Paul, Minnesota, Stati Uniti, 55102
        • Reclutamento
        • United Hospital
        • Contatto:
        • Investigatore principale:
          • David M. King
      • Woodbury, Minnesota, Stati Uniti, 55125
        • Reclutamento
        • Minnesota Oncology Hematology PA-Woodbury
        • Contatto:
        • Investigatore principale:
          • David M. King
    • Mississippi
      • Jackson, Mississippi, Stati Uniti, 39216
        • Reclutamento
        • University of Mississippi Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 601-815-6700
        • Investigatore principale:
          • Amanda Strobel
    • Missouri
      • Cape Girardeau, Missouri, Stati Uniti, 63703
        • Reclutamento
        • Saint Francis Medical Center
        • Investigatore principale:
          • Bryan A. Faller
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 573-334-2230
          • Email: sfmc@sfmc.net
      • Chesterfield, Missouri, Stati Uniti, 63017
        • Reclutamento
        • Saint Luke's Hospital
        • Investigatore principale:
          • Mark J. Fesler
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-205-6936
      • City of Saint Peters, Missouri, Stati Uniti, 63376
        • Reclutamento
        • Siteman Cancer Center at Saint Peters Hospital
        • Investigatore principale:
          • Nancy L. Bartlett
        • Contatto:
      • Columbia, Missouri, Stati Uniti, 65212
        • Reclutamento
        • University of Missouri Children's Hospital
        • Investigatore principale:
          • Barbara A. Gruner
        • Contatto:
      • Creve Coeur, Missouri, Stati Uniti, 63141
        • Reclutamento
        • Siteman Cancer Center at West County Hospital
        • Investigatore principale:
          • Nancy L. Bartlett
        • Contatto:
      • Kansas City, Missouri, Stati Uniti, 64108
        • Reclutamento
        • Children's Mercy Hospitals and Clinics
        • Investigatore principale:
          • Keith J. August
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Investigatore principale:
          • Nancy L. Bartlett
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63141
        • Reclutamento
        • Mercy Hospital Saint Louis
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-251-7066
        • Investigatore principale:
          • Robin D. Hanson
      • St Louis, Missouri, Stati Uniti, 63104
        • Reclutamento
        • Cardinal Glennon Children's Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 314-268-4000
        • Investigatore principale:
          • William S. Ferguson
      • St Louis, Missouri, Stati Uniti, 63129
        • Reclutamento
        • Siteman Cancer Center-South County
        • Investigatore principale:
          • Nancy L. Bartlett
        • Contatto:
      • St Louis, Missouri, Stati Uniti, 63136
        • Reclutamento
        • Siteman Cancer Center at Christian Hospital
        • Investigatore principale:
          • Nancy L. Bartlett
        • Contatto:
    • Nebraska
      • Bellevue, Nebraska, Stati Uniti, 68123
        • Reclutamento
        • Nebraska Medicine-Bellevue
        • Contatto:
        • Investigatore principale:
          • Jill C. Beck
      • Omaha, Nebraska, Stati Uniti, 68114
        • Reclutamento
        • Children's Hospital and Medical Center of Omaha
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 402-955-3949
        • Investigatore principale:
          • Jill C. Beck
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
        • Contatto:
        • Investigatore principale:
          • Jill C. Beck
      • Omaha, Nebraska, Stati Uniti, 68118
        • Reclutamento
        • Nebraska Medicine-Village Pointe
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 402-559-5600
        • Investigatore principale:
          • Jill C. Beck
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89135
        • Reclutamento
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
        • Contatto:
        • Investigatore principale:
          • Joseph L. Lasky
      • Reno, Nevada, Stati Uniti, 89502
        • Reclutamento
        • Renown Regional Medical Center
        • Investigatore principale:
          • Seema L. Rao
        • Contatto:
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03756
        • Reclutamento
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Investigatore principale:
          • Angela Ricci
        • Contatto:
    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Reclutamento
        • Cooper Hospital University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 856-325-6757
        • Investigatore principale:
          • Sushil Ghimire
      • Elizabeth, New Jersey, Stati Uniti, 07207
        • Reclutamento
        • Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 908-994-8000
        • Investigatore principale:
          • Richard A. Drachtman
      • Flemington, New Jersey, Stati Uniti, 08822
        • Reclutamento
        • Hunterdon Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 908-237-2330
        • Investigatore principale:
          • Myron E. Bednar
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • Hackensack University Medical Center
        • Investigatore principale:
          • Burton E. Appel
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 551-996-2897
      • Jersey City, New Jersey, Stati Uniti, 07302
        • Reclutamento
        • Jersey City Medical Center
        • Contatto:
        • Investigatore principale:
          • Richard A. Drachtman
      • Livingston, New Jersey, Stati Uniti, 07039
        • Reclutamento
        • Cooperman Barnabas Medical Center
        • Investigatore principale:
          • Richard A. Drachtman
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 973-322-5200
      • Long Branch, New Jersey, Stati Uniti, 07740
        • Reclutamento
        • Monmouth Medical Center
        • Contatto:
        • Investigatore principale:
          • Richard A. Drachtman
      • Morristown, New Jersey, Stati Uniti, 07960
        • Reclutamento
        • Morristown Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 973-971-5900
        • Investigatore principale:
          • Kathryn L. Laurie
      • Neptune City, New Jersey, Stati Uniti, 07753
        • Reclutamento
        • Jersey Shore Medical Center
        • Investigatore principale:
          • Burton E. Appel
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-776-4240
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Reclutamento
        • Rutgers Cancer Institute of New Jersey
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-7356
        • Investigatore principale:
          • Richard A. Drachtman
      • New Brunswick, New Jersey, Stati Uniti, 08901
        • Reclutamento
        • Saint Peter's University Hospital
        • Investigatore principale:
          • Nibal A. Zaghloul
        • Contatto:
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Reclutamento
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 732-235-8675
        • Investigatore principale:
          • Richard A. Drachtman
      • Newark, New Jersey, Stati Uniti, 07112
        • Reclutamento
        • Newark Beth Israel Medical Center
        • Contatto:
        • Investigatore principale:
          • Teena Bhatla
      • Paterson, New Jersey, Stati Uniti, 07503
        • Reclutamento
        • Saint Joseph's Regional Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 973-754-2207
          • Email: HallL@sjhmc.org
        • Investigatore principale:
          • Alissa Kahn
      • Toms River, New Jersey, Stati Uniti, 08755
        • Reclutamento
        • Community Medical Center
        • Contatto:
        • Investigatore principale:
          • Richard A. Drachtman
    • New Mexico
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • Reclutamento
        • Presbyterian Hospital
        • Investigatore principale:
          • Beeling Armijo
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 505-559-6113
          • Email: wburman@phs.org
      • Albuquerque, New Mexico, Stati Uniti, 87106
        • Sospeso
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Stati Uniti, 12208
        • Reclutamento
        • Albany Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 518-262-5513
        • Investigatore principale:
          • Lauren R. Weintraub
      • Buffalo, New York, Stati Uniti, 14263
        • Reclutamento
        • Roswell Park Cancer Institute
        • Contatto:
        • Investigatore principale:
          • Kara M. Kelly
      • Camillus, New York, Stati Uniti, 13031
        • Reclutamento
        • Hematology Oncology Associates of CNY at Camillus
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 315-472-7504
        • Investigatore principale:
          • Steven M. Duffy
      • East Syracuse, New York, Stati Uniti, 13057
        • Reclutamento
        • Hematology Oncology Associates of Central New York-East Syracuse
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 315-472-7504
        • Investigatore principale:
          • Steven M. Duffy
      • Glens Falls, New York, Stati Uniti, 12801
        • Attivo, non reclutante
        • Glens Falls Hospital
      • Mineola, New York, Stati Uniti, 11501
        • Reclutamento
        • NYU Langone Hospital - Long Island
        • Contatto:
        • Investigatore principale:
          • Chana L. Glasser
      • New Hyde Park, New York, Stati Uniti, 11040
        • Reclutamento
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 718-470-3460
        • Investigatore principale:
          • Arlene S. Redner
      • New York, New York, Stati Uniti, 10032
        • Reclutamento
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Investigatore principale:
          • Nobuko Hijiya
        • Contatto:
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-639-7592
        • Investigatore principale:
          • Christopher J. Forlenza
      • New York, New York, Stati Uniti, 10016
        • Reclutamento
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Investigatore principale:
          • Elizabeth A. Raetz
        • Contatto:
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Mount Sinai Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-824-7309
          • Email: CCTO@mssm.edu
        • Investigatore principale:
          • Pamela R. Merola
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • NYP/Weill Cornell Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 212-746-1848
        • Investigatore principale:
          • Nitya Gulati
      • Rochester, New York, Stati Uniti, 14642
        • Reclutamento
        • University of Rochester
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 585-275-5830
        • Investigatore principale:
          • Carla Casulo
      • Stony Brook, New York, Stati Uniti, 11794
        • Reclutamento
        • Stony Brook University Medical Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-862-2215
        • Investigatore principale:
          • Laura E. Hogan
      • Syracuse, New York, Stati Uniti, 13210
        • Reclutamento
        • State University of New York Upstate Medical University
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 315-464-5476
        • Investigatore principale:
          • Melanie A. Comito
      • The Bronx, New York, Stati Uniti, 10467
        • Reclutamento
        • Montefiore Medical Center - Moses Campus
        • Contatto:
        • Investigatore principale:
          • Alice Lee
      • Webster, New York, Stati Uniti, 14580
      • Williamsville, New York, Stati Uniti, 14221
        • Reclutamento
        • Roswell Park Amherst Center
        • Contatto:
        • Investigatore principale:
          • Kara M. Kelly
    • North Carolina
      • Asheville, North Carolina, Stati Uniti, 28801
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • UNC Lineberger Comprehensive Cancer Center
        • Contatto:
        • Investigatore principale:
          • Natalie S. Grover
      • Charlotte, North Carolina, Stati Uniti, 28203
        • Reclutamento
        • Carolinas Medical Center/Levine Cancer Institute
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-804-9376
        • Investigatore principale:
          • Joel A. Kaplan
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Reclutamento
        • Novant Health Presbyterian Medical Center
        • Contatto:
        • Investigatore principale:
          • Holly Edington
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Investigatore principale:
          • Jessica M. Sun
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 888-275-3853
      • Greenville, North Carolina, Stati Uniti, 27834
        • Reclutamento
        • East Carolina University
        • Contatto:
        • Investigatore principale:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Reclutamento
        • Wake Forest University Health Sciences
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 336-713-6771
        • Investigatore principale:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, Stati Uniti, 58122
    • Ohio
      • Akron, Ohio, Stati Uniti, 44308
        • Reclutamento
        • Children's Hospital Medical Center of Akron
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 330-543-3193
        • Investigatore principale:
          • Lauren R. Draper
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Reclutamento
        • Cincinnati Children's Hospital Medical Center
        • Contatto:
        • Investigatore principale:
          • Robin E. Norris
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • Cleveland Clinic Foundation
        • Contatto:
        • Investigatore principale:
          • Matteo M. Trucco
      • Cleveland, Ohio, Stati Uniti, 44106
        • Reclutamento
        • Rainbow Babies and Childrens Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 216-844-5437
        • Investigatore principale:
          • Duncan S. Stearns
      • Columbus, Ohio, Stati Uniti, 43205
        • Reclutamento
        • Nationwide Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Mark A. Ranalli
      • Dayton, Ohio, Stati Uniti, 45404
        • Reclutamento
        • Dayton Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-228-4055
        • Investigatore principale:
          • Jordan M. Wright
      • Toledo, Ohio, Stati Uniti, 43606
        • Reclutamento
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Jamie L. Dargart
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • University of Oklahoma Health Sciences Center
        • Contatto:
        • Investigatore principale:
          • Rene Y. McNall-Knapp
      • Tulsa, Oklahoma, Stati Uniti, 74136
        • Reclutamento
        • Saint Francis Children's Hospital
        • Investigatore principale:
          • Jill A. Salo
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 918-502-6720
    • Oregon
      • Baker City, Oregon, Stati Uniti, 97814
        • Reclutamento
        • Saint Alphonsus Cancer Care Center-Baker City
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Newberg, Oregon, Stati Uniti, 97132
        • Reclutamento
        • Providence Newberg Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Ontario, Oregon, Stati Uniti, 97914
        • Reclutamento
        • Saint Alphonsus Cancer Care Center-Ontario
        • Contatto:
        • Investigatore principale:
          • Christopher M. Reynolds
      • Oregon City, Oregon, Stati Uniti, 97045
        • Reclutamento
        • Providence Willamette Falls Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Portland, Oregon, Stati Uniti, 97227
        • Reclutamento
        • Legacy Emanuel Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 503-413-2560
        • Investigatore principale:
          • Jason M. Glover
      • Portland, Oregon, Stati Uniti, 97239
        • Reclutamento
        • Oregon Health and Science University
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 503-494-1080
          • Email: trials@ohsu.edu
        • Investigatore principale:
          • Bill H. Chang
      • Portland, Oregon, Stati Uniti, 97213
        • Reclutamento
        • Providence Portland Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
      • Portland, Oregon, Stati Uniti, 97225
        • Reclutamento
        • Providence Saint Vincent Medical Center
        • Investigatore principale:
          • Dan S. Zuckerman
        • Contatto:
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18103
        • Reclutamento
        • Lehigh Valley Hospital-Cedar Crest
        • Investigatore principale:
          • Christopher M. Reynolds
        • Contatto:
      • Danville, Pennsylvania, Stati Uniti, 17822
        • Reclutamento
        • Geisinger Medical Center
        • Investigatore principale:
          • Jagadeesh Ramdas
        • Contatto:
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Reclutamento
        • Penn State Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 717-531-6012
        • Investigatore principale:
          • Lisa M. McGregor
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Children's Hospital of Philadelphia
        • Contatto:
        • Investigatore principale:
          • Leslie S. Kersun
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Thomas Jefferson University Hospital
        • Contatto:
        • Investigatore principale:
          • Michael Wysota
      • Philadelphia, Pennsylvania, Stati Uniti, 19134
        • Reclutamento
        • Saint Christopher's Hospital for Children
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 215-427-8991
        • Investigatore principale:
          • Gregory E. Halligan
      • Pittsburgh, Pennsylvania, Stati Uniti, 15224
        • Reclutamento
        • Children's Hospital of Pittsburgh of UPMC
        • Contatto:
        • Investigatore principale:
          • Jean M. Tersak
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02903
        • Reclutamento
        • Rhode Island Hospital
        • Investigatore principale:
          • Bradley DeNardo
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 401-444-1488
      • Westerly, Rhode Island, Stati Uniti, 02891
        • Reclutamento
        • Smilow Cancer Hospital Care Center - Westerly
        • Contatto:
        • Investigatore principale:
          • Farzana Pashankar
    • South Carolina
      • Boiling Springs, South Carolina, Stati Uniti, 29316
        • Reclutamento
        • Prisma Health Cancer Institute - Spartanburg
        • Investigatore principale:
          • Aniket Saha
        • Contatto:
      • Charleston, South Carolina, Stati Uniti, 29425
        • Reclutamento
        • Medical University of South Carolina
        • Contatto:
        • Investigatore principale:
          • Jacqueline M. Kraveka
      • Columbia, South Carolina, Stati Uniti, 29203
        • Reclutamento
        • Prisma Health Richland Hospital
        • Investigatore principale:
          • Stuart L. Cramer
        • Contatto:
      • Greenville, South Carolina, Stati Uniti, 29605
        • Reclutamento
        • BI-LO Charities Children's Cancer Center
        • Investigatore principale:
          • Aniket Saha
        • Contatto:
      • Greenville, South Carolina, Stati Uniti, 29601
        • Reclutamento
        • Saint Francis Hospital
        • Investigatore principale:
          • Stephen H. Dyar
        • Contatto:
      • Greenville, South Carolina, Stati Uniti, 29607
        • Reclutamento
        • Saint Francis Cancer Center
        • Investigatore principale:
          • Stephen H. Dyar
        • Contatto:
      • Greenville, South Carolina, Stati Uniti, 29615
        • Reclutamento
        • Prisma Health Cancer Institute - Eastside
        • Investigatore principale:
          • Aniket Saha
        • Contatto:
      • Seneca, South Carolina, Stati Uniti, 29672
        • Reclutamento
        • Prisma Health Cancer Institute - Seneca
        • Investigatore principale:
          • Aniket Saha
        • Contatto:
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57117-5134
        • Reclutamento
        • Sanford USD Medical Center - Sioux Falls
        • Contatto:
        • Investigatore principale:
          • Jordan Fritch-Hanson
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37403
        • Reclutamento
        • T C Thompson Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 423-778-7289
        • Investigatore principale:
          • Benjamin A. Mixon
      • Knoxville, Tennessee, Stati Uniti, 37916
        • Reclutamento
        • East Tennessee Childrens Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 865-541-8266
        • Investigatore principale:
          • Susan E. Spiller
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University/Ingram Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 800-811-8480
        • Investigatore principale:
          • Christine M. Smith
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • The Children's Hospital at TriStar Centennial
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 615-342-1919
        • Investigatore principale:
          • Clinton M. Carroll
    • Texas
      • Austin, Texas, Stati Uniti, 78723
        • Reclutamento
        • Dell Children's Medical Center of Central Texas
        • Contatto:
        • Investigatore principale:
          • Shannon M. Cohn
      • Corpus Christi, Texas, Stati Uniti, 78411
        • Reclutamento
        • Driscoll Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Nkechi I. Mba
      • Dallas, Texas, Stati Uniti, 75390
        • Reclutamento
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Investigatore principale:
          • Ksenya Shliakhtsitsava
        • Contatto:
      • Dallas, Texas, Stati Uniti, 75230
        • Reclutamento
        • Medical City Dallas Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 972-566-5588
        • Investigatore principale:
          • Maurizio L. Ghisoli
      • El Paso, Texas, Stati Uniti, 79905
        • Reclutamento
        • El Paso Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Benjamin Carcamo
      • Fort Worth, Texas, Stati Uniti, 76104
        • Reclutamento
        • Cook Children's Medical Center
        • Contatto:
        • Investigatore principale:
          • Karen H. Albritton
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 713-798-1354
          • Email: burton@bcm.edu
        • Investigatore principale:
          • Kala Y. Kamdar
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • UT MD Anderson Cancer Center
        • Contatto:
        • Investigatore principale:
          • Najat C. Daw
      • Lubbock, Texas, Stati Uniti, 79410
        • Reclutamento
        • Covenant Children's Hospital
        • Investigatore principale:
          • Kishor M. Bhende
        • Contatto:
      • Lubbock, Texas, Stati Uniti, 79415
        • Reclutamento
        • UMC Cancer Center / UMC Health System
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 806-775-8590
        • Investigatore principale:
          • Erin K. Barr
      • San Antonio, Texas, Stati Uniti, 78207
        • Reclutamento
        • Children's Hospital of San Antonio
        • Contatto:
        • Investigatore principale:
          • Julie Voeller
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • University of Texas Health Science Center at San Antonio
        • Contatto:
        • Investigatore principale:
          • Allison C. Grimes
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • Methodist Children's Hospital of South Texas
        • Contatto:
        • Investigatore principale:
          • Jose M. Esquilin
      • Temple, Texas, Stati Uniti, 76508
        • Reclutamento
        • Scott and White Memorial Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 254-724-5407
        • Investigatore principale:
          • Nicholas W. McGregor
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84113
        • Reclutamento
        • Primary Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 801-585-5270
        • Investigatore principale:
          • Mallorie B. Heneghan
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Reclutamento
        • Huntsman Cancer Institute/University of Utah
        • Investigatore principale:
          • Boyu Hu
        • Contatto:
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05405
        • Reclutamento
        • University of Vermont and State Agricultural College
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 802-656-8990
          • Email: rpo@uvm.edu
        • Investigatore principale:
          • Jessica L. Heath
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Reclutamento
        • University of Virginia Cancer Center
        • Contatto:
        • Investigatore principale:
          • Brian C. Belyea
      • Falls Church, Virginia, Stati Uniti, 22042
        • Reclutamento
        • Inova Fairfax Hospital
        • Contatto:
        • Investigatore principale:
          • Robin Y. Dulman
      • Norfolk, Virginia, Stati Uniti, 23507
        • Reclutamento
        • Children's Hospital of The King's Daughters
        • Contatto:
        • Investigatore principale:
          • Melissa S. Mark
      • Portsmouth, Virginia, Stati Uniti, 23708-2197
        • Reclutamento
        • Naval Medical Center - Portsmouth
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 757-953-5939
        • Investigatore principale:
          • Karin Brockman
      • Richmond, Virginia, Stati Uniti, 23298
        • Reclutamento
        • VCU Massey Comprehensive Cancer Center
        • Investigatore principale:
          • Jordyn R. Griffin
        • Contatto:
      • Roanoke, Virginia, Stati Uniti, 24014
        • Reclutamento
        • Carilion Children's
        • Contatto:
        • Investigatore principale:
          • Erwood G. Edwards
    • Washington
      • Renton, Washington, Stati Uniti, 98055
        • Sospeso
        • Valley Medical Center
      • Seattle, Washington, Stati Uniti, 98105
        • Reclutamento
        • Seattle Children's Hospital
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 866-987-2000
        • Investigatore principale:
          • Sarah E. Leary
      • Spokane, Washington, Stati Uniti, 99204
        • Reclutamento
        • Providence Sacred Heart Medical Center and Children's Hospital
        • Contatto:
        • Investigatore principale:
          • Judy L. Felgenhauer
      • Tacoma, Washington, Stati Uniti, 98405
        • Reclutamento
        • Mary Bridge Children's Hospital and Health Center
        • Contatto:
        • Investigatore principale:
          • Robert G. Irwin
    • West Virginia
      • Charleston, West Virginia, Stati Uniti, 25304
        • Reclutamento
        • Vandalia Health/CAMC Institute for Academic Medicine
        • Investigatore principale:
          • Mohamad H. Badawi
        • Contatto:
      • Huntington, West Virginia, Stati Uniti, 25701
        • Reclutamento
        • Edwards Comprehensive Cancer Center
        • Investigatore principale:
          • Mark A. Ranalli
        • Contatto:
    • Wisconsin
      • Burlington, Wisconsin, Stati Uniti, 53105
        • Reclutamento
        • Aurora Cancer Care-Southern Lakes VLCC
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Cudahy, Wisconsin, Stati Uniti, 53110
        • Reclutamento
        • Aurora Saint Luke's South Shore
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Germantown, Wisconsin, Stati Uniti, 53022
        • Reclutamento
        • Aurora Health Care Germantown Health Center
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Grafton, Wisconsin, Stati Uniti, 53024
        • Reclutamento
        • Aurora Cancer Care-Grafton
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Green Bay, Wisconsin, Stati Uniti, 54311
        • Reclutamento
        • Aurora BayCare Medical Center
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Green Bay, Wisconsin, Stati Uniti, 54301
        • Reclutamento
        • Saint Vincent Hospital Cancer Center Green Bay
        • Investigatore principale:
          • Catherine A. Long
        • Contatto:
      • Kenosha, Wisconsin, Stati Uniti, 53142
        • Reclutamento
        • Aurora Cancer Care-Kenosha South
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • La Crosse, Wisconsin, Stati Uniti, 54601
        • Reclutamento
        • Gundersen Lutheran Medical Center
        • Contatto:
        • Investigatore principale:
          • Kurt Oettel
      • Madison, Wisconsin, Stati Uniti, 53792
        • Reclutamento
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Investigatore principale:
          • Priyanka Pophali
        • Contatto:
      • Madison, Wisconsin, Stati Uniti, 53718
        • Reclutamento
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Investigatore principale:
          • Priyanka Pophali
        • Contatto:
      • Marinette, Wisconsin, Stati Uniti, 54143
        • Reclutamento
        • Aurora Bay Area Medical Group-Marinette
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Marshfield, Wisconsin, Stati Uniti, 54449
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Children's Hospital of Wisconsin
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 414-955-4727
          • Email: MACCCTO@mcw.edu
        • Investigatore principale:
          • Michael J. Burke
      • Milwaukee, Wisconsin, Stati Uniti, 53209
        • Reclutamento
        • Aurora Cancer Care-Milwaukee
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Milwaukee, Wisconsin, Stati Uniti, 53215
        • Reclutamento
        • Aurora Saint Luke's Medical Center
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Milwaukee, Wisconsin, Stati Uniti, 53233
        • Reclutamento
        • Aurora Sinai Medical Center
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Mukwonago, Wisconsin, Stati Uniti, 53149
        • Reclutamento
        • ProHealth D N Greenwald Center
        • Contatto:
        • Investigatore principale:
          • Timothy R. Wassenaar
      • Oconomowoc, Wisconsin, Stati Uniti, 53066
        • Reclutamento
        • ProHealth Oconomowoc Memorial Hospital
        • Investigatore principale:
          • Timothy R. Wassenaar
        • Contatto:
          • Site Public Contact
          • Numero di telefono: 262-928-7878
      • Oshkosh, Wisconsin, Stati Uniti, 54904
        • Reclutamento
        • Vince Lombardi Cancer Clinic - Oshkosh
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Racine, Wisconsin, Stati Uniti, 53406
        • Reclutamento
        • Aurora Cancer Care-Racine
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Reclutamento
        • Vince Lombardi Cancer Clinic-Sheboygan
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Sheboygan, Wisconsin, Stati Uniti, 53081
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Sheboygan
        • Investigatore principale:
          • Catherine A. Long
        • Contatto:
      • Sturgeon Bay, Wisconsin, Stati Uniti, 54235-1495
        • Reclutamento
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
        • Investigatore principale:
          • Catherine A. Long
        • Contatto:
      • Summit, Wisconsin, Stati Uniti, 53066
        • Reclutamento
        • Aurora Medical Center in Summit
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Two Rivers, Wisconsin, Stati Uniti, 54241
        • Reclutamento
        • Vince Lombardi Cancer Clinic-Two Rivers
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • Waukesha, Wisconsin, Stati Uniti, 53188
        • Reclutamento
        • UW Cancer Center at ProHealth Care
        • Investigatore principale:
          • Timothy R. Wassenaar
        • Contatto:
      • Wauwatosa, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Aurora Cancer Care-Milwaukee West
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall
      • West Allis, Wisconsin, Stati Uniti, 53227
        • Reclutamento
        • Aurora West Allis Medical Center
        • Contatto:
        • Investigatore principale:
          • Rebecca E. McFall

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 5 anni a 60 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must be 5 to 60 years of age at the time of enrollment

  • Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]) with stage I or II disease

  • Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm)

  • Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained

  • Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.

    • Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
  • Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2

  • Patients =< 17 years of age must have a Lansky performance score of >= 50

  • Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment):

    • 2 to < 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
    • 6 to < 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
    • 10 to < 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
    • 13 to < 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
    • >= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight

  • Total bilirubin =< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Aspartate aminotransferase (AST) =< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Alanine aminotransferase (ALT) =< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)

  • Diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of > 92% on room air

  • Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Exclusion Criteria:

  • Patients with nodular lymphocyte predominant Hodgkin lymphoma

  • Patients with a history of active interstitial pneumonitis or interstitial lung disease

  • Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients

  • Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills

  • Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to > 10 mg daily predniSONE for patients >= 18 years or > 0.5 mg/kg [up to 10 mg/day] for patients < 18 years) or other immunosuppressive medications within 14 days prior to enrollment

    • Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=< 10 mg daily for patients >= 18 years or =< 0.5 mg/kg [up to 10 mg/day] predniSONE equivalents) are permitted in the absence of active autoimmune disease
    • Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
    • Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids.
  • Patients with peripheral neuropathy > grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome

  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen

  • Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL

  • Prior solid organ transplant

  • Prior allogeneic stem cell transplantation

  • Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin [BCG], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted

  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential

  • Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment

  • Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer

    • Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin
    • WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab
  • All patients and/or their parents or legal guardians must sign a written informed consent

  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm A (ABVD)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm B (ABVD, brentuximab vedotin, nivolumab)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm C (ABVD, eBEACOPP or eBPDac, ISRT)

See Detailed Description.

Given IV

Altri nomi:
  • Cytoxan
  • CTX
  • (-)-ciclofosfamide
  • 2H-1,3,2-ossazafosforina, 2-[bis(2-cloroetil)ammino]tetraidro-, 2-ossido, monoidrato
  • Carloxan
  • Ciclofosfamidica
  • Ciclofosfamide
  • Ciclossale
  • Clafen
  • Clafene
  • CP monoidrato
  • Cella CYCLO
  • Cicloblastina
  • Ciclofosfame
  • Ciclofosfamide monoidrato
  • Ciclofosfamidum
  • Ciclofosfano
  • Ciclofosfanum
  • Ciclostina
  • Citofosfano
  • Fosfaseron
  • Genoxal
  • Genuxale
  • Ledossina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamide
  • WR-138719
  • Asta B518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Given PO

Altri nomi:
  • Deltason
  • Orasone
  • .delta.1-Cortisone
  • 1,2-deidrocortisone
  • Adason
  • Cortancyl
  • Dacortin
  • DeCortin
  • Decortisil
  • Decorton
  • Delta 1-cortisone
  • Delta-cupola
  • Deltacortene
  • Deltacortisone
  • Deltadeidrocortisone
  • Deltisone
  • Deltra
  • Econosone
  • Lisacort
  • Meprosona-F
  • Metacortandracina
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracorto
  • Perrigo Prednisone
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Prednimento
  • Prednisone Intensolo
  • Prednisonum
  • Prednitone
  • Promifen
  • Rayos
  • Servisone
  • SK-Prednisone

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Oncovin
  • Kyocristina
  • Leurocristina solfato
  • Leurocristina, solfato
  • Vincasar
  • Vincosid
  • Vincrex
  • Vincristina, solfato

Ancillary studies

Given IV

Altri nomi:
  • Demetil Epipodofillotossina Etilidina Glucoside
  • EPEG
  • Ultimo
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP16213
  • VP-16213

Given IV

Altri nomi:
  • Etopofos

Given PO

Altri nomi:
  • (11beta)-11,17,21-Triidrossipregna-1,4-dien-3,20-dione
  • .delta.1-Idrocortisone
  • Adnisolone
  • Aprednislon
  • Capsoid
  • Cortalone
  • Cortisone
  • Dacortin H
  • Decaprednil
  • Decortin H
  • Delta(1) Idrocortisone
  • Delta-Cortef
  • Delta Diona
  • Delta-F
  • Delta-foricolo
  • Delta1-deidro-idrocortisone
  • Deltacortrile
  • Deltaidrocortisone
  • Deltasolone
  • Deltidrosol
  • Dasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilson
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolone
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralone
  • Meti Derm
  • Meticortelone
  • Opredson
  • Panafcortelone
  • Precortisil
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolonum
  • Prelone
  • Prenilone
  • Sterane

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Undergo ISRT

Altri nomi:
  • ISRT

Given PO

Altri nomi:
  • PCZ
  • Matulano
  • PCB
  • Natulanar
  • Benzammide, N-(1-metiletil)-4-[(2-metilidrazino) metil]-, monocloridrato (9CI)
  • Ibenzmethyzine cloridrato
  • MIH cloridrato
  • Natulan
  • Naturale
  • NCI-C01810
  • p-(N'-metilidrazinometil)-N-isopropilbenzammide cloridrato
  • p-Toluamide, N-isopropil-.alfa.-(2-metilidrazino)-, monocloridrato (8CI)
  • PCB cloridrato
  • Ro 4 6467/1
  • Ro 4-6467/1
  • NCI C01810
  • NCIC01810
Sperimentale: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Undergo ISRT

Altri nomi:
  • ISRT
Sperimentale: Arm E (ABVD, AVD)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm F (ABVD, brentuximab vedotin, nivolumab)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)
Sperimentale: Arm G (ABVD, eBEACOPP or eBPDac, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.

Given IV

Altri nomi:
  • Cytoxan
  • CTX
  • (-)-ciclofosfamide
  • 2H-1,3,2-ossazafosforina, 2-[bis(2-cloroetil)ammino]tetraidro-, 2-ossido, monoidrato
  • Carloxan
  • Ciclofosfamidica
  • Ciclofosfamide
  • Ciclossale
  • Clafen
  • Clafene
  • CP monoidrato
  • Cella CYCLO
  • Cicloblastina
  • Ciclofosfame
  • Ciclofosfamide monoidrato
  • Ciclofosfamidum
  • Ciclofosfano
  • Ciclofosfanum
  • Ciclostina
  • Citofosfano
  • Fosfaseron
  • Genoxal
  • Genuxale
  • Ledossina
  • Mitoxan
  • Neosar
  • Revimmune
  • Syklofosfamide
  • WR-138719
  • Asta B518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Given PO

Altri nomi:
  • Deltason
  • Orasone
  • .delta.1-Cortisone
  • 1,2-deidrocortisone
  • Adason
  • Cortancyl
  • Dacortin
  • DeCortin
  • Decortisil
  • Decorton
  • Delta 1-cortisone
  • Delta-cupola
  • Deltacortene
  • Deltacortisone
  • Deltadeidrocortisone
  • Deltisone
  • Deltra
  • Econosone
  • Lisacort
  • Meprosona-F
  • Metacortandracina
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracorto
  • Perrigo Prednisone
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Prednimento
  • Prednisone Intensolo
  • Prednisonum
  • Prednitone
  • Promifen
  • Rayos
  • Servisone
  • SK-Prednisone

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Given IV

Altri nomi:
  • Oncovin
  • Kyocristina
  • Leurocristina solfato
  • Leurocristina, solfato
  • Vincasar
  • Vincosid
  • Vincrex
  • Vincristina, solfato

Ancillary studies

Given IV

Altri nomi:
  • Demetil Epipodofillotossina Etilidina Glucoside
  • EPEG
  • Ultimo
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP16213
  • VP-16213

Given IV

Altri nomi:
  • Etopofos

Given PO

Altri nomi:
  • (11beta)-11,17,21-Triidrossipregna-1,4-dien-3,20-dione
  • .delta.1-Idrocortisone
  • Adnisolone
  • Aprednislon
  • Capsoid
  • Cortalone
  • Cortisone
  • Dacortin H
  • Decaprednil
  • Decortin H
  • Delta(1) Idrocortisone
  • Delta-Cortef
  • Delta Diona
  • Delta-F
  • Delta-foricolo
  • Delta1-deidro-idrocortisone
  • Deltacortrile
  • Deltaidrocortisone
  • Deltasolone
  • Deltidrosol
  • Dasolone
  • Di-Adreson-F
  • Dontisolon D
  • Estilson
  • Fisopred
  • Frisolona
  • Gupisone
  • Hostacortin H
  • Hydeltra
  • Hydeltrasol
  • Klismacort
  • Kuhlprednon
  • Lenisolone
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metacortandralone
  • Meti Derm
  • Meticortelone
  • Opredson
  • Panafcortelone
  • Precortisil
  • Pred-Clysma
  • Predeltilone
  • Predni-Coelin
  • Predni-Helvacort
  • Prednicortelone
  • Prednisolonum
  • Prelone
  • Prenilone
  • Sterane

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Undergo ISRT

Altri nomi:
  • ISRT

Given PO

Altri nomi:
  • PCZ
  • Matulano
  • PCB
  • Natulanar
  • Benzammide, N-(1-metiletil)-4-[(2-metilidrazino) metil]-, monocloridrato (9CI)
  • Ibenzmethyzine cloridrato
  • MIH cloridrato
  • Natulan
  • Naturale
  • NCI-C01810
  • p-(N'-metilidrazinometil)-N-isopropilbenzammide cloridrato
  • p-Toluamide, N-isopropil-.alfa.-(2-metilidrazino)-, monocloridrato (8CI)
  • PCB cloridrato
  • Ro 4 6467/1
  • Ro 4-6467/1
  • NCI C01810
  • NCIC01810
Sperimentale: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)

Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm D.

Given IV

Altri nomi:
  • Adriamicina
  • 5,12-naftacenedione, 10-[(3-ammino-2,3,6-trideossi-alfa-L-lisso-esopiranosil)ossi]-7,8, 9,10-tetraidro-6,8,11-triidrossi -8-(idrossiacetil)-1-metossi-, cloridrato, (8S-cis)- (9CI)
  • ADM
  • Adriacin
  • Adriamicina cloridrato
  • Adriamicina PFS
  • Adriamicina RDF
  • ADRIAMICINA, CLORIDRATO
  • Adriblastina
  • Adrimedac
  • Cloridrato di Doxorrubicina
  • DOX
  • DOXO-CELL
  • Doxolem
  • Doxorubicina cloridrato
  • Doxorubicina.HCl
  • Doxorubina
  • Farmiblastina
  • FI 106
  • FI-106
  • idrossidaunorubicina
  • Rubex
  • FI106

Undergo blood sample collection

Altri nomi:
  • Raccolta di campioni biologici
  • Biocampione raccolto
  • Raccolta di campioni
  • Raccolta campione

Ancillary studies

Given IV

Altri nomi:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Coniugato anticorpo-farmaco anti-CD30 SGN-35
  • Anticorpo monoclonale anti-CD30-MMAE SGN-35
  • Anticorpo monoclonale anti-CD30-Monomethylaurstatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Altri nomi:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilare CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab biosimilare ABP 206
  • BCD-263
  • Nivolumab biosimilare BCD-263
  • BMS936558
  • ONO4538

Given IV

Altri nomi:
  • 4-(Dimetiltriazeno)imidazolo-5-carbossammide
  • 5-(Dimetiltriazeno)imidazolo-4-carbossammide
  • Asercit
  • Biocarbazina
  • Dacarbazina
  • Dacarbazina Almirall
  • Dacarbazina - DTIC
  • Dacatico
  • Dakarbazin
  • Deticene
  • Detimedac
  • DIC
  • Dimetil (triazeno) imidazolocarbossammide
  • Dimetil Triazeno Imidazolo Carbossammide
  • dimetil-triazeno-imidazolo carbossammide
  • Dimetil-triazeno-imidazolo-carbossimide
  • DTIC
  • DTIC-Dome
  • Faldetico
  • Imidazolo Carbossammide
  • Imidazolo Carbossammide Dimetiltriazeno
  • WR-139007

Given IV

Altri nomi:
  • 29060 LE
  • 29060-LE
  • Esal
  • Velban
  • Velbe
  • Velsar
  • VINCALEUKOBLASTINE

Given IV

Altri nomi:
  • Bleocin
  • Blenoxano
  • Blanoxan
  • BleMomycine
  • Bleo-cellula
  • Bleo-S
  • Bleolem
  • Bleomicina Sulfas
  • Bleomicina solfato
  • Bleomicini Sulfas
  • Blexano
  • Olio Bleo

Undergo CT and/or PET-CT

Altri nomi:
  • CT
  • GATTO
  • TAC
  • Tomografia assiale computerizzata
  • Tomografia computerizzata
  • tomografia
  • Tomografia assiale computerizzata (procedura)
  • Scansione tomografia computerizzata (CT).
  • Scansione CAT diagnostica
  • Tipo di servizio di scansione CAT diagnostica

Undergo FDG-PET

Altri nomi:
  • 18FDG
  • F DG
  • fluorodesossiglucosio F 18
  • Fluodeossiglucosio (18F)
  • Fluodeossiglucosio F18
  • Fluoro-18 2-Fluoro-2-deossi-D-Glucosio
  • Fluorodesossiglucosio F18

Undergo MRI and/or PET-MRI

Altri nomi:
  • Risonanza magnetica
  • Scansione di immagini a risonanza magnetica
  • Imaging medico, risonanza magnetica/risonanza magnetica nucleare
  • SIG
  • Imaging RM
  • Scansione MRI
  • Imaging NMR
  • RMN
  • Risonanza Magnetica Nucleare
  • Imaging a risonanza magnetica (MRI)
  • sMRI
  • Imaging a risonanza magnetica (procedura)
  • RM strutturale

Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

Altri nomi:
  • Imaging medico, tomografia a emissione di positroni
  • ANIMALE DOMESTICO
  • Scansione animale
  • Scansione di tomografia a emissione di positroni
  • Tomografia ad emissione di positroni
  • P.T
  • Tomografia a emissione di positroni (procedura)

Undergo ISRT

Altri nomi:
  • ISRT

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS) in rapid early responder (RER) patients
Lasso di tempo: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first

Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin-nivolumab) against those randomized to standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
PFS in slow-early responder (SER) patients
Lasso di tempo: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first

Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy against arms containing standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall survival (OS) in RER patients
Lasso di tempo: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years).

Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
OS in SER patients
Lasso di tempo: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients.

Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
OS for entire patient population
Lasso di tempo: Time from randomization to death due to any cause, assessed at 12 years after the last enrollment

Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization. Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population.

Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
PFS for favorable risk patients
Lasso di tempo: Up to 12 years

Will be estimated in patients with favorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
PFS for unfavorable risk patients
Lasso di tempo: Up to 12 years

Will be estimated in patients with unfavorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
PFS for entire population
Lasso di tempo: Up to 12 years

PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

Up to 12 years
Event-free survival (EFS)
Lasso di tempo: Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment

Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned versus (vs.) not assigned to receive radiaton therapy (RT), and compared using the log-rank test.

Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
Incidence of adverse events (AEs)
Lasso di tempo: Assessed up to 12 years from last enrollment

Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs. Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests. The maximum grade for each toxicity will be recorded for each patient. The rates and confidence intervals for these toxicities will be provided. Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients.

Assessed up to 12 years from last enrollment
Patient reported outcomes (PRO)-CTCAE
Lasso di tempo: Assessed up to 12 years from last enrollment

Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older. For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used. For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time. Additionally, the worst severity and/or interference over the entire course will be summarized. The changes among main time points will be calculated. The results will be provided for the whole population and compared between subpopulations by arms and by age groups. Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms.

Assessed up to 12 years from last enrollment
Patient-reported fatigue
Lasso di tempo: Baseline up to 1 year from end of study treatment

Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System initiatives. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Patient-reported cognitive deficits
Lasso di tempo: Baseline up to 1 year from end of study treatment

Will be measured by validated short forms from the Neuro-QoL initiative. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Patient-reported health-related quality of life
Lasso di tempo: Baseline up to 1 year from end of study treatment

Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

Baseline up to 1 year from end of study treatment
Incidence of self-reported late morbidities
Lasso di tempo: Assessed up to 12 years from last enrollment

Will be collected by using validated measures from the St. Jude Life Cohort. The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method. The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests.

Assessed up to 12 years from last enrollment
Effect of metabolic tumor burden (MTV) on PFS
Lasso di tempo: At baseline prior to initiation of therapy

MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

At baseline prior to initiation of therapy
Effect of total lesion glycolysis (TLG) on PFS
Lasso di tempo: At baseline prior to initiation of therapy

TLG will be measured at baseline using FDG-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

At baseline prior to initiation of therapy
Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity
Lasso di tempo: After Cycle 2 of treatment (1 cycle = 28 days)

PET2 Response will be compared by race and ethnicity using Fisher exact tests.

After Cycle 2 of treatment (1 cycle = 28 days)
Contribution of SDOH to PFS by race and ethnicity
Lasso di tempo: Assessed up to 12 years after last enrollment

Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white [NHW], non-Hispanic black [NHB], Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.

Assessed up to 12 years after last enrollment
Contribution of SDOH to OS by race and ethnicity
Lasso di tempo: Assessed up to 12 years after last enrollment

K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.

Assessed up to 12 years after last enrollment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS comparison between treatment arms for each age group
Lasso di tempo: Up to 12 years

Will be compared between a standard chemotherapy approach and an IO therapy approach within different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years) using log-rank tests. Cox regression models will be constructed to evaluate the treatment effects for different age groups while considering the impact of other potentially prognostic variables including baseline demographics and clinical risk factors. PFS and corresponding confidence intervals for each age group will be estimated with the Kaplan-Meier method, overall and by treatment arms. In additional models, age may be evaluated as a continuous variable with potentially non-linear effects on PFS.

Up to 12 years
Concordance and discordance of 5-point score (PS) visual PET assessments
Lasso di tempo: At baseline, post cycle 2, and at end of systemic therapy

The concordance and discordance of 5-PS visual PET assessment from rapid central review and local institutional review will be evaluated at each of the timepoints. Will collect and retrospectively review local vs. central review concordance rates. For discordant cases, will document the differences in treatments if only local review or only central review were performed

At baseline, post cycle 2, and at end of systemic therapy
Association between FDG PET parameters obtained by automated measurements and PFS
Lasso di tempo: At baseline, post cycle 2, and at the end of therapy

The association between FDG PET parameters obtained by automated measurements using convolutional neural networks and PFS will be evaluated in this aim. The PET parameters of interest are total MTV and TLG, tumor standardized uptake value change. PET parameters will be obtained based on artificial intelligence (AI) based measurements. The effect of these PET measurements will be evaluated by Cox regression models.

At baseline, post cycle 2, and at the end of therapy
Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement
Lasso di tempo: At baseline, post cycle 2, and at the end of therapy

Will compare AI derived automated quantitative FDG-PET measurement extraction and physician-based manual quantitative PET measurement with Spearman rank correlation coefficients for each extracted PET metric.

At baseline, post cycle 2, and at the end of therapy
Incidence of patient reported adverse events and provider adverse event reporting
Lasso di tempo: Assessed up to 12 years

Will be collected by PRO-CTCAE and Ped-PRO-CTCAE. The patient reported AEs will be compared to provider reported AEs reported descriptively.

Assessed up to 12 years
Association between self-reported race/ethnicity and dimensional SDOH
Lasso di tempo: Assessed up to 12 years

Will be evaluated by Chi-square tests or Fisher exact tests for sparse data. Will also calculate the area deprivation index (derived from patient-reported address and zip code to census block-group data for patients treated in the United States, and the Canadian Index of Multiple Deprivation for patients treated in Canada) and investigate its association with race/ethnicity and SDOH.

Assessed up to 12 years
Post-relapse/post-progression OS by race/ethnicity and select SDOH measures
Lasso di tempo: Assessed up to 12 years

The K-M curves will be presented together with p-values via log-rank tests across the different race/ethnicity groups for each treatment arm. Cox proportional hazard models to evaluate the relationship between race/ethnicity and post-relapse OS will be constructed.

Assessed up to 12 years
Completion rate of PRO and health-related quality of life contact forms
Lasso di tempo: At 1 year off treatment

Will be evaluated for the first 450 eligible participants.

At 1 year off treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Kara M Kelly, Roswell Park Cancer Institute

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 maggio 2023

Completamento primario (Stimato)

28 aprile 2031

Completamento dello studio (Stimato)

28 aprile 2031

Date di iscrizione allo studio

Primo inviato

6 gennaio 2023

Primo inviato che soddisfa i criteri di controllo qualità

6 gennaio 2023

Primo Inserito (Effettivo)

9 gennaio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NCI-2022-10845
  • U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2022-10845 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • AHOD2131 (Altro identificatore: CTEP)
  • AHOD2131 (Altro identificatore: Children's Oncology Group)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi